Literature DB >> 31363174

Causes of nasoenteral tube obstruction in tertiary hospital patients.

José L A Borges1,2, Ivens A O De Souza3, Michele C V Costa3, Fabiana Ruotolo3, Livia M G Barbosa3, Isac De Castro4, Paulo C Ribeiro3.   

Abstract

BACKGROUND/
OBJECTIVES: Obstruction of the nasoenteral tube is one of the complications of enteral nutrition therapy, and its causes and frequency of occurrence are not well understood. To evaluate the causes of enteral nutrition feeding tube obstruction. To study the time elapsed between the beginning of the nutrition therapy and the obstruction of the tube. SUBJECTS/
METHODS: This was a retrospective cohort study of 1170 patients aged 18 years or older who were hospitalized at Sírio-Libanês Hospital between January 2015 and October 2017, and who were undergoing enteral nutrition therapy delivered using an infusion pump through a nasogastric or nasoenteral tube. The study population included 683 (58%) men and 487 (42%) women. The median age was 79 years. Of these, 1084 patients received enteral nutrition and medication through the feeding tube, and 86 received medication alone. Variables investigated as causes of feeding tube obstruction were the administration of medication through the tube, type of diet, and use of symbiotics.
RESULTS: Obstruction rates were 4% for up to 40 days of observation and 8% for the total observation time. The time for obstruction of 10% of the tubes in patients receiving rivaroxaban, linagliptin, metformin, and nystatin was 16, 19, 20, and 28 days, respectively.
CONCLUSIONS: The main cause of nasoenteral tube obstruction (odds ratio) was the combination of metformin (2.0), nystatin (3.1), linagliptin (4.3), rivaroxaban (2.4), and a high-protein diet (1.9). Overall, proper tube care and strict compliance with tubal drug delivery guidelines can result in low tube obstruction rates.

Entities:  

Mesh:

Year:  2019        PMID: 31363174     DOI: 10.1038/s41430-019-0475-0

Source DB:  PubMed          Journal:  Eur J Clin Nutr        ISSN: 0954-3007            Impact factor:   4.016


  2 in total

1.  Multicentre, cluster-randomized clinical trial of algorithms for critical-care enteral and parenteral therapy (ACCEPT).

Authors:  Claudio M Martin; Gordon S Doig; Daren K Heyland; Teresa Morrison; William J Sibbald
Journal:  CMAJ       Date:  2004-01-20       Impact factor: 8.262

2.  Viscosity and flow-rate of three high-energy, high-fibre enteral nutrition formulas.

Authors:  P Casas-Augustench; J Salas-Salvadó
Journal:  Nutr Hosp       Date:  2009 Jul-Aug       Impact factor: 1.057

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.